{"entity":{"id":"endocrine-resistance","kind":"term","name":"Endocrine resistance","aka":["endocrine-resistant"],"tldr":"When hormone therapy stops controlling a hormone-driven breast cancer, either quickly (primary) or after years (acquired).","summary":"Primary resistance: relapse within 2 years of adjuvant ET or progression within 6 months of first-line metastatic ET. Secondary: later relapse or progression. Mechanisms: ESR1 mutations, PI3K/AKT/mTOR activation, cyclin D1/CDK4 amplification, RB loss, FGFR1 amplification, HER2 activation, lineage plasticity. Determines eligibility for INAVO120-type regimens (relapse on/within 12 months of adjuvant ET).","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Hormone_therapy_(oncology)","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Hormone_therapy_(oncology)"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":["estrogen-receptor","pik3ca","cdk4-6"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Resistance"},"route":"/terms/endocrine-resistance/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"target":[{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/"},{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/"}],"term":[{"id":"aromatase-inhibitor","kind":"term","name":"Aromatase inhibitor","route":"/terms/aromatase-inhibitor/"},{"id":"hormone-receptor-status","kind":"term","name":"Hormone receptor status (ER / PR)","route":"/terms/hormone-receptor-status/"},{"id":"hyperglycaemia","kind":"term","name":"Hyperglycaemia (PI3K/AKT inhibitor class effect)","route":"/terms/hyperglycaemia/"},{"id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/"},{"id":"receptor-conversion-breast","kind":"term","name":"Receptor conversion: when the receptors change between the primary and a recurrence","route":"/terms/receptor-conversion-breast/"},{"id":"serd","kind":"term","name":"Selective oestrogen receptor degrader (SERD)","route":"/terms/serd/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"}],"pathway":[{"id":"cell-cycle-engine-cdks","kind":"pathway","name":"The cell-cycle engine (cyclins & CDKs)","route":"/pathways/cell-cycle-engine-cdks/"}]}}